返回 Agenda
Session 18: FDA Review of Clinical Trial Data in an NDA or BLA
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
This session will provide insights into the How and the What of Agency pre-approval review of safety data in marketing applications via the 21st Century Review Process and JumpStart.